In the observational TOCERRA study by Lauper et al ,1 the authors showed that tocilizumab (TOC; either as monotherapy or combination therapy) had superior drug retention than tumour necrosis factor inhibitors (TNFi; as monotherapy or combination therapy), in patients with rheumatoid arthritis with prior exposure to at least one biologic disease-modifying antirheumatic drug (bDMARD). Yet, efficacy (measured by Clinical Disease Activity Index (CDAI) change over time) was the same! The authors offered the following astute explanations: (1) CDAI does not comprehensively assess drug efficacy; (2) different tolerance between TOC and TNFi groups; or (3) retention captures something that is not evaluated by CDAI. I would like to expand on these explanations, since this phenomenon has previously appeared in this journal. When a patient …

中文翻译：

---

当二元和连续响应不一致时

在 Lauper 等人的观察性 TOCERRA 研究 1 中，作者表明，在类风湿性关节炎患者中，托珠单抗（TOC；作为单一疗法或联合疗法）比肿瘤坏死因子抑制剂（TNFi；作为单一疗法或联合疗法）具有更好的药物保留之前接触过至少一种生物疾病缓解抗风湿药 (bDMARD)。然而，疗效（通过临床疾病活动指数 (CDAI) 随时间的变化来衡量）是一样的！作者给出了以下精辟的解释：（1）CDAI没有全面评估药物疗效；(2)TOC与TNFi组间耐受性不同；或 (3) 留存率捕获了 CDAI 未评估的内容。我想扩展这些解释，因为这种现象以前出现在这个期刊上。当患者...